FDA Fast Tracks 225Ac-FL-020 in mCRPC

News
Article

The FDA has granted fast track designation to 225Ac-FL-020, a promising PSMA-targeting radionuclide drug conjugate for metastatic castration-resistant prostate cancer.

  • A fast track designation has been granted to 225Ac-FL-020 for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

  • 225Ac-FL-020 works to target prostate-specific membrane antigen (PSMA).

  • With this fast track designation, 225Ac-FL-020 shows potential to provide a novel therapeutic option for patients with mCRPC.

The FDA has granted a fast track designation to 225Ac-FL-02 for the treatment of patients with mCRPC.1

"The FDA fast track designation for 225Ac-FL-020 underscores the critical need for innovative and effective treatments for mCRPC", said Steffen Heeger, MD, MSc, chief medical officer of Full-Life, in a press release. "This designation will enable us to collaborate more closely with the FDA throughout the development process, potentially accelerating the availability of 225Ac-FL-020 to patients."

Conceptual image for viral ethiology of prostate cancer. 3D illustration showing viruses infecting prostate gland which develops cancerous tumor: © Dr_Microbe - stock.adobe.com

Conceptual image for viral ethiology of prostate cancer. 3D illustration showing viruses infecting prostate gland which develops cancerous tumor: © Dr_Microbe - stock.adobe.com

225Ac-FL-020 is a novel, potential best-in-class, next-generation actinium-225 (225Ac)-based PSMA-targeting radionuclide drug conjugate that employs targeted alpha-radiotherapy designed to selectively attack cancer cells. This approach reduces damage to healthy tissues.

Preclinically, radiolabeled FL-020 demonstrated a promising in vivo biodistribution profile. High and sustained tumor uptake was observed, as well as fast systemic clearance. Further, 225Ac-FL-020 led to robust antitumor activity and had a favorable safety profile.

In May 2024, the company gained FDA clearance of its investigational new drug application to begin trials of 225Ac-FL-020 in the US and globally.2 Now, a phase 1 trial plans to examine 225Ac-FL-020’s safety, tolerability, and antitumor activity when used as a treatment option for patients with mCRPC.

This phase 1 study plans to lay the foundation for further clinical development and aims to establish 225Ac-FL-020 as a valuable therapeutic option for patients with mCRPC.

REFERENCES:
  1. Full-Life Technologies granted FDA fast track designation for 225Ac-FL-020 for the treatment of metastatic castration-resistant prostate cancer. News release. Full-Life Technologies. July 2, 2024. Accessed July 3, 2024. https://tinyurl.com/ycyjkpde
  2. Full-Life Technologies announces clearance from FDA of IND application for 225Ac-FL-020 for the treatment of metastatic castration-resistant prostate cancer. News release. Full-Life Technologies. May 30, 2024. Accessed July 3, 2024. https://www.full-life.com/media/press-releases/24
Recent Videos
Toni K. Choueiri, MD, with the Oncology Brothers presenting slides
Toni K. Choueiri, MD, with the Oncology Brothers presenting slides
Toni K. Choueiri, MD, with the Oncology Brothers presenting slides
Toni K. Choueiri, MD, with the Oncology Brothers presenting slides
Toni K. Choueiri, MD, with the Oncology Brothers presenting slides
Related Content